Cargando…
Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease
RATIONALE AND OBJECTIVE: Patients with chronic obstructive pulmonary disease (COPD), usually diagnosed after the 6th decade, frequently suffer from comorbidities. Whether COPD patients 50 years or younger (Young COPD) have similar comorbidities with the same frequency and mortality impact as aged-ma...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516817/ https://www.ncbi.nlm.nih.gov/pubmed/36167533 http://dx.doi.org/10.1186/s12931-022-02191-7 |
_version_ | 1784798786487320576 |
---|---|
author | Divo, Miguel J. Marin, José M. Casanova, Ciro Cabrera Lopez, Carlos Pinto-Plata, Victor M. Marin-Oto, Marta Polverino, Francesca de-Torres, Juan P. Billheimer, Dean Celli, Bartolome R. |
author_facet | Divo, Miguel J. Marin, José M. Casanova, Ciro Cabrera Lopez, Carlos Pinto-Plata, Victor M. Marin-Oto, Marta Polverino, Francesca de-Torres, Juan P. Billheimer, Dean Celli, Bartolome R. |
author_sort | Divo, Miguel J. |
collection | PubMed |
description | RATIONALE AND OBJECTIVE: Patients with chronic obstructive pulmonary disease (COPD), usually diagnosed after the 6th decade, frequently suffer from comorbidities. Whether COPD patients 50 years or younger (Young COPD) have similar comorbidities with the same frequency and mortality impact as aged-matched controls or older COPD patients is unknown. METHODS: We compared comorbidity number, prevalence and type in 3 groups of individuals with ≥ 10 pack-years of smoking: A Young (≤ 50 years) COPD group (n = 160), an age-balanced control group without airflow obstruction (n = 125), and Old (> 50 years) COPD group (n = 1860). We also compared survival between the young COPD and control subjects. Using Cox proportional model, we determined the comorbidities associated with mortality risk and generated Comorbidomes for the “Young” and “Old” COPD groups. RESULTS: The severity distribution by GOLD spirometric stages and BODE quartiles were similar between Young and Old COPD groups. After adjusting for age, sex, and pack-years, the prevalence of subjects with at least one comorbidity was 31% for controls, 77% for the Young, and 86% for older COPD patients. Compared to controls, “Young” COPDs’ had a nine-fold increased mortality risk (p < 0.0001). “Comorbidomes” differed between Young and Old COPD groups, with tuberculosis, substance use, and bipolar disorders being distinct comorbidities associated with increased mortality risk in the Young COPD group. CONCLUSIONS: Young COPD patients carry a higher comorbidity prevalence and mortality risk compared to non-obstructed control subjects. Young COPD differed from older COPD patients by the behavioral-related comorbidities that increase their risk of premature death. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-02191-7. |
format | Online Article Text |
id | pubmed-9516817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95168172022-09-29 Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease Divo, Miguel J. Marin, José M. Casanova, Ciro Cabrera Lopez, Carlos Pinto-Plata, Victor M. Marin-Oto, Marta Polverino, Francesca de-Torres, Juan P. Billheimer, Dean Celli, Bartolome R. Respir Res Research RATIONALE AND OBJECTIVE: Patients with chronic obstructive pulmonary disease (COPD), usually diagnosed after the 6th decade, frequently suffer from comorbidities. Whether COPD patients 50 years or younger (Young COPD) have similar comorbidities with the same frequency and mortality impact as aged-matched controls or older COPD patients is unknown. METHODS: We compared comorbidity number, prevalence and type in 3 groups of individuals with ≥ 10 pack-years of smoking: A Young (≤ 50 years) COPD group (n = 160), an age-balanced control group without airflow obstruction (n = 125), and Old (> 50 years) COPD group (n = 1860). We also compared survival between the young COPD and control subjects. Using Cox proportional model, we determined the comorbidities associated with mortality risk and generated Comorbidomes for the “Young” and “Old” COPD groups. RESULTS: The severity distribution by GOLD spirometric stages and BODE quartiles were similar between Young and Old COPD groups. After adjusting for age, sex, and pack-years, the prevalence of subjects with at least one comorbidity was 31% for controls, 77% for the Young, and 86% for older COPD patients. Compared to controls, “Young” COPDs’ had a nine-fold increased mortality risk (p < 0.0001). “Comorbidomes” differed between Young and Old COPD groups, with tuberculosis, substance use, and bipolar disorders being distinct comorbidities associated with increased mortality risk in the Young COPD group. CONCLUSIONS: Young COPD patients carry a higher comorbidity prevalence and mortality risk compared to non-obstructed control subjects. Young COPD differed from older COPD patients by the behavioral-related comorbidities that increase their risk of premature death. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-02191-7. BioMed Central 2022-09-27 2022 /pmc/articles/PMC9516817/ /pubmed/36167533 http://dx.doi.org/10.1186/s12931-022-02191-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Divo, Miguel J. Marin, José M. Casanova, Ciro Cabrera Lopez, Carlos Pinto-Plata, Victor M. Marin-Oto, Marta Polverino, Francesca de-Torres, Juan P. Billheimer, Dean Celli, Bartolome R. Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease |
title | Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease |
title_full | Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease |
title_fullStr | Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease |
title_full_unstemmed | Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease |
title_short | Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease |
title_sort | comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516817/ https://www.ncbi.nlm.nih.gov/pubmed/36167533 http://dx.doi.org/10.1186/s12931-022-02191-7 |
work_keys_str_mv | AT divomiguelj comorbiditiesandmortalityriskinadultsyoungerthan50yearsofagewithchronicobstructivepulmonarydisease AT marinjosem comorbiditiesandmortalityriskinadultsyoungerthan50yearsofagewithchronicobstructivepulmonarydisease AT casanovaciro comorbiditiesandmortalityriskinadultsyoungerthan50yearsofagewithchronicobstructivepulmonarydisease AT cabreralopezcarlos comorbiditiesandmortalityriskinadultsyoungerthan50yearsofagewithchronicobstructivepulmonarydisease AT pintoplatavictorm comorbiditiesandmortalityriskinadultsyoungerthan50yearsofagewithchronicobstructivepulmonarydisease AT marinotomarta comorbiditiesandmortalityriskinadultsyoungerthan50yearsofagewithchronicobstructivepulmonarydisease AT polverinofrancesca comorbiditiesandmortalityriskinadultsyoungerthan50yearsofagewithchronicobstructivepulmonarydisease AT detorresjuanp comorbiditiesandmortalityriskinadultsyoungerthan50yearsofagewithchronicobstructivepulmonarydisease AT billheimerdean comorbiditiesandmortalityriskinadultsyoungerthan50yearsofagewithchronicobstructivepulmonarydisease AT cellibartolomer comorbiditiesandmortalityriskinadultsyoungerthan50yearsofagewithchronicobstructivepulmonarydisease AT comorbiditiesandmortalityriskinadultsyoungerthan50yearsofagewithchronicobstructivepulmonarydisease |